Pancreatic CancerMAGIPACNCT05428358
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
A study testing Preoperative MRI in people with Pancreatic Cancer and Pancreatic Neoplasm, run by University of Aarhus at 3 sites in Denmark.
Trial summary
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Pancreatic Cancer, Pancreatic Neoplasm, Liver Metastases
- What is being tested?
- Preoperative MRI
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 3 sitesDenmark
- Study dates
- 30 Aug 2022to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
- No liver metastases on CT
- At least 18 years old and able to provide informed consent
- Expected pancreatic ductal adenocarcinoma based on CT scan
Who cannot join
- Metastatic disease
- Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
- Comorbidity rendering major surgery unfeasible (inoperable)
- No informed consent
- Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
- Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
- MRI with liver-specific contrast performed during standard workup.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark3 sites, 3 recruiting
- Recruiting
Aalborg University Hospital
Aalborg
Mogens Stender, MD, PhD
- Recruiting
Aarhus University Hospital
Aarhus, 8200
Jakob Kirkegård, MD, PhD, +4522900604, jakob.kirkegaard@auh.rm.dk
Frank V Mortensen, MD, DMSc, +45222517296, frmort@rm.dk
- Recruiting
Rigshospitalet
Copenhagen
Carsten P Hansen, MD, DMSc
About this study
Official title: Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Read the detailed description
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasm, Liver Metastases
- Being tested
- Preoperative MRI
- Keywords
- magnetic resonance imaging
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Preoperative MRIDiagnostic test
Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
| Study group | Role | What they receive |
|---|---|---|
| Preoperative MRI | Experimental | MRI before surgery. Receives: Diagnostic Test: Preoperative MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in treatment strategy
Change in treatment strategy from intended curative resection to other treatment based on MRI scan
Measured: 1 week
Secondary outcomes (8)
Liver metastases
Proportion of patients who had liver metastases detected on MRI
Measured: 1 week
Surgery
Proportion of patients who made it to surgery/exploration
Measured: 1 month
Resection
Proportion of patients in each arm who had a pancreatic resection performed
Measured: 1 month
Intraoperatively detected liver metastases
Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.
Measured: 1 month
Overall survival (1-year)
1-year overall survival.
Measured: 1 year
Overall survival (3-year)
3-year overall survival.
Measured: 3 years
Recurrence-free survival
Recurrence-free survival according to final treatment strategy.
Measured: 3 years
Healthcare costs
Healthcare costs in patients with change of treatment.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2022
- Study start30 Aug 2022
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frank Mortensen, MD, DMSc, Study chair, Aarhus University HospitalJakob Kirkegård, MD, PhD, Principal investigator, Aarhus University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05428358
- Sponsor's protocol ID
- MAGIPAC
- Acronym
- MAGIPAC
- Status last verified
- Apr 2026
- First submitted
- 16 Jun 2022
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to Danish law, no individual-level data can be shared.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
- ClinicalTrials.gov ID
- NCT05428358
- Acronym / sponsor ID
- MAGIPAC / MAGIPAC
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasm, Liver Metastases
- Keywords
- magnetic resonance imaging
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet, Aalborg University Hospital
- Study start
- 30 Aug 2022 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 23 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Detailed description
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Preoperative MRI | Experimental | Diagnostic Test: Preoperative MRIMRI before surgery. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
- No liver metastases on CT
- At least 18 years old and able to provide informed consent
- Expected pancreatic ductal adenocarcinoma based on CT scan
Key exclusion criteria (7 listed)
- Metastatic disease
- Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
- Comorbidity rendering major surgery unfeasible (inoperable)
- No informed consent
- Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Preoperative MRIPreoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection | Diagnostic test | Preoperative MRI |
Primary outcome
Change in treatment strategy
Time frame: 1 week
Change in treatment strategy from intended curative resection to other treatment based on MRI scan
8 secondary outcomes
Liver metastases
Time frame: 1 week
Surgery
Time frame: 1 month
Resection
Time frame: 1 month
Intraoperatively detected liver metastases
Time frame: 1 month
Overall survival (1-year)
Time frame: 1 year
Overall survival (3-year)
Time frame: 3 years
Recurrence-free survival
Time frame: 3 years
Healthcare costs
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No. Due to Danish law, no individual-level data can be shared.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frank Mortensen, MD, DMSc study chair
Aarhus University Hospital
Jakob Kirkegård, MD, PhD principal investigator
Aarhus University Hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Preoperative MRI in people with Pancreatic Cancer and Pancreatic Neoplasm, run by University of Aarhus at 3 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jakob Kirkegård, MD, PhD (+4522900604, jakob.kirkegaard@auh.rm.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in treatment strategy (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.